RECOVER Continues Enrollment And Adds New Work Package

SOS-COVID

The RECOVER primary care study (work package 2, WP2), SOS-COVID, started in March 2020 and enrolled their first patients in the Netherlands on April 14th. The study aims to generate evidence about milder and/or undiagnosed SARS-CoV-2 infection, risk factors for a complicated course of disease, as well as to track the impact of the disease when managed outside the hospital. Since March, over 600 patients were included in the trial from 8 different countries; the Netherlands, Belgium, Georgia, Spain, Germany, Moldova, Hungary and Ireland. An interim analysis showed that 10% of patients with respiratory tract infection included in this study tested positive for SARS-CoV-2.

The social sciences team of WP2 has conducted interviews with patients and general practitioners early in the pandemic in 6 European countries. The goal was to generate an understanding of their perspectives in receiving and providing primary care during the pandemic. The interviews are finished and the data are currently being analyzed.

MERMAIDS ARI

The MERMAIDS ARI and MERMAIDS ARI 2.0 studies are part of the PREPARE consortium and work package 3 (WP3) of RECOVER, respectively. Since its reactivation, the MERMAIDS ARI study has enrolled over 160 patients, including 30 COVID-19 patients. To allow for broad geographical coverage across Europe, more and targeted biological sampling, enrolment of children and enriching the cohort, the MERMAIDS ARI 2.0 study was set up. MERMAIDS ARI 2.0 has now enrolled a little over 70 patients, of which 60 COVID-19 patients, in 4 European countries. Another 5 countries are in the startup process. Despite the challenging COVID-19 situation throughout Europe, participating sites are showing a big effort to recruit patients.

A survey to assess perceptions and preparedness of European healthcare workers (HCWs) for COVID-19 is also part of RECOVER’s WP3. Two survey rounds included in total 2,289 HCWs from 40 European countries. Data analysis was finalized and a manuscript was submitted for publication on 20 November 2020.

REMAP-CAP

A new work package was added to RECOVER, work package 8 (WP8): the REMAP-CAP study. The study is an adaptive platform trial (APT) focused on determining the optimal set of treatments for patients with severe community-acquired pneumonia (CAP). As an adaptive platform, REMAP-CAP is specifically designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment. Due to the continued global spread of COVID-19, the platform has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward. With the ability to improve the design according to new insights and already having the clinical trial infrastructure in place to implement these insights swiftly, various interventions can be tested simultaneously within multiple therapeutic domains. REMAP-CAP is funded under the European Union’s PREPARE and RECOVER consortia.